Use of extracorporeal photopheresis in kidney transplant recipients with antibody-mediated rejection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study describes the clinical, biological, and histological evolution of kidney transplant recipients who developed antibody-mediated rejection and were treated with extracorporeal photopheresis, over a one-year period. It uses data from patients followed at Besançon and Lille between 2016 and 2023 to characterize outcomes after treatment. The report focuses on real-world experiences, documenting patterns in rejection, graft function, and biological markers without a predefined intervention protocol. The study aims to provide descriptive insights into the safety and potential impact of this therapy in routine care settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Kidney transplant recipients followed at the University Hospitals of Besançon and Lille between September 1, 2016, and August 31, 2023
* Patients with antibody-mediated rejection (as confirmed by histological analysis of the renal biopsy)
* Rejection treated with extracorporeal photopheresis
* Subjects who do not object to the use of their personal data and/or biological samples
* Subjects affiliated with, or beneficiaries of, the French social security system

Exclusion Criteria:

* Patients with acute rejection
* Pregnant women, women in labor, or breastfeeding mothers
* Individuals deprived of liberty by judicial or administrative decision; individuals receiving compulsory psychiatric care; or individuals admitted to a healthcare or social institution for reasons other than research participation
* Minors
* Adults under legal protection or unable to provide informed consent
* Subjects without health insurance coverage
* Subjects currently within an exclusion period from another study, or as listed in the "national volunteer registry"

Where it's running

• Centre Hospitalier Universitaire de Besançon
  Besançon, France Recruiting

Study contacts

• Study coordinator: Charline Vauchy, PhD.
• Email: cvauchy@chu-besancon.fr
• Phone: +33381218875

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Siltuximab for antibody-mediated rejection after lung transplant

  This study will test whether adding siltuximab, an IL‑6 blocker, to standard treatment is safe and tolerable for adults hospitalized with antibody-mediated rejection after lung transplant.

  Recruiting at 2 sites Phase 1 Washington University School of Medicine · St Louis, Missouri and 1 other locations · NCT06990711

• BiTE therapy for chronic active antibody-mediated rejection after kidney transplant

  This study tests whether a BCMA×CD3 Bispecific T-cell Engager can help kidney transplant patients with chronic active antibody-mediated rejection.

  Recruiting Phase 4 West China Hospital · Chengdu, Sichuan · NCT07689578

• B cells in antibody-mediated kidney transplant rejection: their characteristics and what they react to.

  This project will test whether B cells taken from kidney transplant patients with suspected antibody-mediated rejection produce antibodies that react to donor HLA, other targets, or gut microbes.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris and 1 other locations · NCT07134491

• CID-103 for active and chronic active ABMR in kidney transplant patients

  A two-part study will test CID-103, an anti-CD38 infusion, to see if it is safe and helps adults with active or chronic active antibody-mediated rejection after kidney transplant.

  Recruiting Phase 1/2 CASI pharmaceuticals, Inc. · Beijing, Beijing Municipality and 3 other locations · NCT07641426

• Evaluating extracorporeal photopheresis for subclinical lung transplant rejection

  This study is testing if a light-based treatment called extracorporeal photopheresis can help lung transplant patients who have early signs of rejection feel better and improve their health.

  Recruiting Medical University of Vienna · Vienna and 6 other locations · NCT06112951

• Collecting blood samples from patients undergoing plasma exchange

  This study is collecting blood samples from patients with immune-related diseases who are having plasma exchange to see how their antibody levels change during treatment and to use the samples for future research.

  Recruiting University of Iowa · Iowa City, Iowa · NCT05004493

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.